Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer

Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer

No ideal serum biomarker currently exists for the early diagnosis of colorectal cancer (CRC). Therefore, it is urgent that accurate and reliable serum biomarkers be identified.

Magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) was used to screen serum samples from CRC patients and healthy controls.

Patients with colorectal cancer

Inclusion criteria

• histologically confirmed colorectal cancer
• aged 18 years or older
• have provided written informed consent

Exclusion criteria

• refusal to participate

Healthy controls

Inclusion criteria

• no cancer history
• aged 18 years or older
• have provided written informed consent

Exclusion criteria

• refusal to participate
• have first-degree relative with a known history of colorectal cancer